SCHEMBL10043874

SCHEMBL10043874

Cc1cc2c(cn1)cc(-c1cc(NC(=O)NC(=O)c3cc(C)oc3C)ccc1C)c(=O)n2C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.39
NPC1 O15118 8/20 0.39
RAB9A P51151 8/20 0.39
HPGD P15428 2/20 0.37
RECQL P46063 1/20 0.37
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
AKR1C1 Q04828 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
MAPK1 P28482 2/20 0.36
TP53 P04637 1/20 0.36
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.35
MAPK14 Q16539 2/20 0.34
MAPT P10636 3/20 0.34
ALDH1A1 P00352 2/20 0.34
LMNA P02545 1/20 0.34
KRAS P01116 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043683 0.93 NPC1 (0.46) SYKNPC1RAB9AHPGDRECQL
SCHEMBL10043864 0.87 SYK (0.44) SYKNPC1RAB9AMAPK1TP53
SCHEMBL10043870 0.85 RAB9A (0.40) SYKNPC1RAB9ASMN1; SMN2TP53
SCHEMBL10043857 0.85 POLB (0.45) SYKNPC1RAB9ASMN1; SMN2TP53
SCHEMBL10043850 0.84 SYK (0.50) SYKNPC1RAB9AHPGDSMN1; SMN2
SCHEMBL10043861 0.83 S1PR1 (0.46) SYKNPC1RAB9ATP53KMT2A
SCHEMBL10043877 0.83 RAB9A (0.45) SYKNPC1RAB9AHPGDSMN1; SMN2
SCHEMBL13462639 0.82 SYK (0.42) SYKNPC1RAB9APOLBMAPK14
SCHEMBL10043869 0.82 GAA (0.45) SYKNPC1RAB9ATP53POLB
SCHEMBL10043859 0.82 SYK (0.42) SYKNPC1RAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885NPC1 4095/4885RAB9A 1818/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885NPC1 4095/4885RAB9A 1818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.